Abstract
Screening programs for cancer demand a major allocation of public health resources. The evidence required to justify the introduction of such programs therefore needs to be unassailable, based on randomized trials with mortality reduction from the cancer in question as the primary endpoint. These trials, which could be called primary, are of necessity large and of long duration, since the yearly risk of dying from a cancer is small in absolute terms for almost all cancers at almost all ages. For example, there are few female populations for which the yearly risk of dying from breast cancer is more than 0.1% at any age.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Day NE, Williams DRR, Khaw KT. 1989. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 59: 954–958.
Eddy DM. 1980. Screening for cancer: Theory, analysis and design. Englewood Cliffs, NJ: Prentice-Hall.
van Oortmarssen GJ, Habbema JDF. 1995. Duration of preclinical cervical cancer and reduction in incidences of invasive cancers following negative Pap smears. Int J Epidemiol 24: 300–307.
Day NE. 1985. Estimating the sensitivity of a screening test. J Epidemiol Commun Health 39: 364–366.
Paci E, Duffy SW. 1991. Modelling the analysis of breast cancer screening programmes: Sensitivity, lead time and predictive value in the Florence district programme (1975–1986). Int J Cancer 20: 852–858.
Day NE, Walter SD. 1984. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics 40: 1–14.
Day NE, Duffy SW. 1996. Trial design based on surrogate endpoints — application to comparison of different screening frequencies. J R Stat Soc Series A 159: 49–60.
Duffy SW, Tabar L, Fagerberg G, et al. 1991. Breast screening, prognostic factors and survival results from the Swedish Two County study. Br J Cancer 64: 1133–1138.
Walter SD, Day NE. 1983. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 118: 865–885.
Walter SD, Stilt LW. 1987. Evaluating the survival of cancer cases detected by screening. Stat Med 6: 885–900.
Tabar L, Fagerberg G, Chen HH, et al. 1995. Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality and histology. J Med Screening 2: 94–98.
Tabar L, Fagerberg G, Chen HH, et al. 1995. Efficiency of breast screening by age. Cancer 75: 2507–2517.
Atkin WS, Cusick J, Corthoves JMA, et al. 1993. Prevention of colorectal cancer by once only sigmoidoscopy. Lancet 341: 736–740.
Prentice RL. 1989. Surrogate endpoints in clinical trials: definition and operating criteria. Stat Med 8: 431–440.
Freedman LS, Granbard BI, Schatzkin A. 1992. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11: 167–178.
Eckhardt S, Badellino F, Murphy GP. 1994. UICC meeting on breast screening in premenopausal women in developed countries. Br J Cancer 56: 1–5.
NHSBSP. 1989. Quality assurance guidelines for mammography. U.K. Department of Health.
NHSBSP. 1993. Objectives for the breast screening programme. U.K. Department of Health.
Day NE, McCann J, Camilleri-Ferrante C, et al. 1995. Monitoring interval cancers in breast screening programmes: the East Anglian experience. J Med Screening 2: 180–185.
Boyes DA, Morrison B, Knox EG, et al. 1982. A cohort study for cervical cancer screening in British Columbia. Clin Invest Med 5: 1–29.
IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. 1986. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policy. Br Med J 113: 214–226.
Gustafsson L, Adami HO. 1989. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 60: 132–141.
Gustafsson L, Adami HO. 1990. Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. Br J Cancer 61: 903–908.
Gustafsson L, Adami HO. 1990. Optimization of cervical cancer screening. Cancer Causes Control 3: 125–136.
Oortmarssen GJ van, Habbema JDF, van Maas PJ, et al. 1990. A model for breast screening. Cancer 66: 1601–1612.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Day, N.E. (1996). The theoretical basis for cancer screening. In: Miller, A.B. (eds) Advances in Cancer Screening. Cancer Treatment and Research, vol 86. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1265-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1265-9_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8539-7
Online ISBN: 978-1-4613-1265-9
eBook Packages: Springer Book Archive